CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Mylan Laboratories Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Mylan Laboratories Ltd
Plot No 564/A/22
Road No 92, Jubilee Hills
Phone: +91 4030866666p:+91 4030866666 Hyderabad, 500034  India Fax: +91 4030866699f:+91 4030866699
This is a Subsidiary, click here for the Parent Company
Business Summary
Mylan Laboratories Limited, formerly Matrix Laboratories Limited, is a manufacturer and supplier of active pharmaceutical ingredients (APIs) for a range of therapeutic categories, including antibacterials, central nervous system agents, antihistamine/anti-asthmatics, cardiovasculars, antivirals, antidiabetics, antifungals, proton pump inhibitors and pain management drugs. Anti Bacterials include Ciprofloxacin, Gatifloxacin, Norfloxacin, and Levofloxacin Hemihydrate. As of March 31, 2011, it held 40% equity interest in Matrix Laboratories BVBA, Belgium through its wholly owned subsidiary Matrix Laboratories BV, Netherlands. The Company’s three principal products include Valacyclovir, Citalopram and Teno Lami 300 milligram/300 milligram. In October 2012, SMS Pharmaceuticals Ltd sold its manufacturing unit in Visakhapatnam to the Company. In February 2013, SMS Pharmaceuticals Ltd sold/transferred Unit-VI to Mylan Laboratories Limited.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
---Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/20113/31/2011Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Acting Chief Executive Officer, Chief Operating Officer, Executive Director B. HariBabu 47 1/1/2012 1/1/2001
Chief Compliance Officer, General Counsel RajeevMukundan 39 12/1/2009 12/1/2009
Head - Finance, Executive Director SusantoBanerjee 45 1/1/2012 12/1/2009
3 additional Officers and Directors records available in full report.

General Information
Number of Employees: 3,005 (As of 3/31/2009)
Outstanding Shares: 156,338,811 (As of 3/31/2011)
Shareholders: 33,944
Fax Number: +91 4030866699


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023